Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26560441 | 0.90 | CYP2A6 (0.71) | CYP2A6PDGFRBPDGFRAEGFRCYP11B2 | |
| SCHEMBL26561200 | 0.86 | ESR2 (0.58) | PDGFRBPDGFRAEGFRGAKESR2 | |
| SCHEMBL26560431 | 0.86 | CYP2A6 (0.61) | CYP2A6PDGFRBPDGFRAEGFRCYP11B2 | |
| SCHEMBL26560420 | 0.86 | CYP2A6 (0.61) | CYP2A6PDGFRBPDGFRAEGFRCYP11B2 | |
| SCHEMBL26549349 | 0.86 | CYP2A6 (0.61) | CYP2A6PDGFRBPDGFRAEGFRCYP11B2 | |
| SCHEMBL26568911 | 0.86 | CYP2A6 (0.61) | CYP2A6PDGFRBPDGFRAEGFRCYP11B2 | |
| SCHEMBL26549058 | 0.86 | CYP2A6 (0.61) | CYP2A6PDGFRBPDGFRAEGFRCYP11B2 | |
| SCHEMBL26558156 | 0.85 | PDGFRB (0.62) | CYP2A6PDGFRBPDGFRAEGFRCYP19A1 | |
| SCHEMBL26553124 | 0.85 | CYP11B2 (0.69) | CYP2A6CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL26549061 | 0.83 | CYP2A6 (0.58) | CYP2A6PDGFRBPDGFRAEGFRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337527-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | AOC1, ODC1, PIEZO1 | CYP2A6 2788/4885PDGFRB 4867/4885PDGFRA 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.